Evidence map›Paper›PMID 42838937›Full record

ArticleBlood cancer journal2026

SETD2 is a novel and druggable dependency in IMiD/CELMoD resistant multiple myeloma models.

Sarah A Bird, Marco P Licciardello, Salomon Morales, Mara Mandelia, Enze Liu, Yakinthi Chrisochoidou, James Smith, Amy Wilson, Jack Cheung, Shannon Martin and 5 more

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood cancer journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Sarah A BirdThe Institute of Cancer Research, London, UK.ORCID http://orcid.org/0000-0001-8080-0937
Marco P LicciardelloThe Institute of Cancer Research, London, UK.
Salomon MoralesThe Institute of Cancer Research, London, UK.
Mara MandeliaThe Institute of Cancer Research, London, UK.
Enze LiuMiami Miller School of Medicine, University of Miami, Miami, FL, USA.
Yakinthi ChrisochoidouThe Institute of Cancer Research, London, UK.
James SmithThe Institute of Cancer Research, London, UK.
Amy WilsonThe Institute of Cancer Research, London, UK.
Jack CheungThe Institute of Cancer Research, London, UK.
Shannon MartinThe Institute of Cancer Research, London, UK.
Yigen LiThe Institute of Cancer Research, London, UK.ORCID http://orcid.org/0000-0002-0420-214X
Fernando J SialanaThe Institute of Cancer Research, London, UK.ORCID http://orcid.org/0000-0001-9083-1657
Brian A WalkerMiami Miller School of Medicine, University of Miami, Miami, FL, USA.
Paul A ClarkeThe Institute of Cancer Research, London, UK.ORCID http://orcid.org/0000-0001-9342-1290
Charlotte PawlynThe Institute of Cancer Research, London, UK. charlotte.pawlyn@icr.ac.uk.ORCID http://orcid.org/0000-0002-7190-0028

Funding

Cancer Research UK (CRUK) C47608/A29957Wellcome TrustWellcome Trust (Wellcome) S_4267
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID42838937
PMCPMC13642255

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.